These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38751755)

  • 21. Thymectomy in severe (Myasthenia Gravis Foundation of America classes IV-V) generalized myasthenia gravis: is the game really worth the candle?
    Brascia D; Lucchi M; Aprile V; Guida M; Ricciardi R; Rea F; Comacchio GM; Schiavon M; Marino MC; Margaritora S; Meacci E; Spagni G; Evoli A; Lorenzoni G; De Iaco G; De Palma A; Marulli G
    Eur J Cardiothorac Surg; 2023 May; 63(5):. PubMed ID: 37162377
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Minimal Manifestation Status Indicates a Stable State in Myasthenia Gravis: A Quantitative Study.
    Jiang P; Li J; Li HY; Zhang B; Yue YX; Wang SY; Zi XC; Liu SS; Li YF; Jiao LD; Li HF
    Front Neurol; 2022; 13():880045. PubMed ID: 35677340
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of ravulizumab in patients with generalized myasthenia gravis by time from diagnosis: A post hoc subgroup analysis of the CHAMPION MG study.
    Howard JF; Vu T; Mantegazza R; Kushlaf H; Suzuki S; Wiendl H; Beasley KN; Liao S; Meisel A;
    Muscle Nerve; 2024 May; 69(5):556-565. PubMed ID: 38380691
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance.
    Murai H; Suzuki S; Hasebe M; Fukamizu Y; Rodrigues E; Utsugisawa K
    Ther Adv Neurol Disord; 2021; 14():17562864211001995. PubMed ID: 33796147
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and immune-related factors associated with exacerbation in adults with well-controlled generalized myasthenia gravis.
    Bi Z; Zhan J; Zhang Q; Gao H; Yang M; Ge H; Gui M; Lin J; Bu B
    Front Immunol; 2023; 14():1177249. PubMed ID: 37266422
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors affecting outcome in ocular myasthenia gravis.
    Mazzoli M; Ariatti A; Valzania F; Kaleci S; Tondelli M; Nichelli PF; Galassi G
    Int J Neurosci; 2018 Jan; 128(1):15-24. PubMed ID: 28625092
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Individualized regimen of low-dose rituximab monotherapy for new-onset AChR-positive generalized myasthenia gravis.
    Du Y; Li C; Hao YF; Zhao C; Yan Q; Yao D; Li L; Zhang W
    J Neurol; 2022 Aug; 269(8):4229-4240. PubMed ID: 35243555
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Promising efficacy of Low-Dose rituximab in Muscle specific kinase antibody positive Myasthenia Gravis.
    Yang X; Zhang W; Chang X; Li Z; Du R; Guo J
    Neurosci Lett; 2024 Jan; 818():137561. PubMed ID: 37984485
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduced quality of life in myasthenia gravis patients: A study on 185 patients from China.
    Wu X; Li RY; Ye XB; Wang N
    Front Neurol; 2022; 13():1072861. PubMed ID: 36712441
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation of Quantitative Myasthenia Gravis and Myasthenia Gravis Activities of Daily Living scales in the MGTX study.
    McPherson T; Aban I; Duda PW; Farzaneh-Far R; Wolfe GI; Kaminski HJ; Cutter G; Lee I;
    Muscle Nerve; 2020 Aug; 62(2):261-266. PubMed ID: 32369631
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Zytux in Refractory Myasthenia Gravis: A Multicenter, Open-Labeled, Clinical Trial Study of Effectiveness and Safety of a Rituximab Biosimilar.
    Fatehi F; Moradi K; Okhovat AA; Shojatalab G; Sedighi B; Boostani R; Sarraf P; Haghi Ashtiani B; Ghasemi M; Moussavi S; Anjidani N; Nafissi S
    Front Neurol; 2021; 12():682622. PubMed ID: 34512504
    [No Abstract]   [Full Text] [Related]  

  • 32. Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis.
    Oyama M; Okada K; Masuda M; Shimizu Y; Yokoyama K; Uzawa A; Kawaguchi N; Ikeguchi R; Hoshino Y; Hatano T; Ozawa Y; Nakahara J; Aizawa H; Kitagawa K; Hattori N; Kuwabara S; Murai H; Suzuki S
    Ther Adv Neurol Disord; 2020; 13():1756286420904207. PubMed ID: 32215054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rituximab as induction therapy in refractory myasthenia gravis: 18 month follow-up study.
    Singh N; Goyal V
    J Neurol; 2019 Jul; 266(7):1596-1600. PubMed ID: 30919039
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quality of life in refractory generalized myasthenia gravis: A rapid review of the literature.
    Garzón-Orjuela N; van der Werf L; Prieto-Pinto LC; Lasalvia P; Castañeda-Cardona C; Rosselli D
    Intractable Rare Dis Res; 2019 Nov; 8(4):231-238. PubMed ID: 31890449
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efgartigimod and Ravulizumab for Treating Acetylcholine Receptor Auto-antibody-Positive (AChR-Ab+) Generalized Myasthenia Gravis: Indirect Treatment Comparison.
    van Steen C; Celico L; Spaepen E; Hagenacker T; Meuth SG; Ruck T; Smith AG; Bodicoat DH; de Francesco M; Iannazzo S
    Adv Ther; 2024 Jun; 41(6):2486-2499. PubMed ID: 38642198
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab.
    Vissing J; Jacob S; Fujita KP; O'Brien F; Howard JF;
    J Neurol; 2020 Jul; 267(7):1991-2001. PubMed ID: 32189108
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial.
    Howard JF; Nowak RJ; Wolfe GI; Freimer ML; Vu TH; Hinton JL; Benatar M; Duda PW; MacDougall JE; Farzaneh-Far R; Kaminski HJ; ; Barohn R; Dimachkie M; Pasnoor M; Farmakidis C; Liu T; Colgan S; Benatar MG; Bertorini T; Pillai R; Henegar R; Bromberg M; Gibson S; Janecki T; Freimer M; Elsheikh B; Matisak P; Genge A; Guidon A; David W; Habib AA; Mathew V; Mozaffar T; Hinton JL; Hewitt W; Barnett D; Sullivan P; Ho D; Howard JF; Traub RE; Chopra M; Kaminski HJ; Aly R; Bayat E; Abu-Rub M; Khan S; Lange D; Holzberg S; Khatri B; Lindman E; Olapo T; Sershon LM; Lisak RP; Bernitsas E; Jia K; Malik R; Lewis-Collins TD; Nicolle M; Nowak RJ; Sharma A; Roy B; Nye J; Pulley M; Berger A; Shabbir Y; Sachdev A; Patterson K; Siddiqi Z; Sivak M; Bratton J; Small G; Kohli A; Fetter M; Vu T; Lam L; Harvey B; Wolfe GI; Silvestri N; Patrick K; Zakalik K; Duda PW; MacDougall J; Farzaneh-Far R; Pontius A; Hoarty M
    JAMA Neurol; 2020 May; 77(5):582-592. PubMed ID: 32065623
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study.
    Siddiqi ZA; Nowak RJ; Mozaffar T; O'Brien F; Yountz M; Patti F;
    Muscle Nerve; 2021 Dec; 64(6):662-669. PubMed ID: 34590717
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Safety of Immunotherapies in Refractory Myasthenia Gravis: A Systematic Review and Meta-Analysis.
    Feng X; Song Z; Wu M; Liu Y; Luo S; Zhao C; Zhang W
    Front Neurol; 2021; 12():725700. PubMed ID: 34925206
    [No Abstract]   [Full Text] [Related]  

  • 40. Therapeutic and Immunoregulatory Effects of Tacrolimus in Patients with Refractory Generalized Myasthenia Gravis.
    Wu H; Wang Z; Xi J; Liu J; Yan C; Song J; Wang L; Jing S; Wang Y; Zhao C
    Eur Neurol; 2020; 83(5):500-507. PubMed ID: 32932253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.